Daniel Emil Levy

USPTO Granted Patents = 14 (Patent Applications = 20)

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 30(Granted Patents)

Company Filing History:

7 out of 183

Ptc Therapeutics, Inc.

patents

3 out of 23

Signpath Pharma, Inc.

patents

2 out of 3,685

Johns Hopkins University

patents

4. 1 out of 1

Allosteros Therapeutics, Inc.

patent

5. 1 out of 832,718

Other

patents

Years Active: 2018-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12325706 - Polymorphic form of sepiapterin (2025-06-10),

2. 12269829 - Polymorphs of sepiapterin and salts thereof (2025-04-08),

3. 12213982 - Pharmaceutical compositions comprising sepiapterin and uses thereof (2025-02-04),

4. 11773097 - Polymorphs of sepiapterin and salts thereof (2023-10-03),

5. 11752154 - Pharmaceutical compositions comprising sepiapterin and uses thereof (2023-09-12),

6. 11746119 - Cardiopathy-reducing phosphodiester lipids (2023-09-05),

7. 11643424 - Cardiopathy-reducing phosphodiester lipids (2023-05-09),

8. 11325908 - CaMKII inhibitors and uses thereof (2022-05-10),

9. 11130760 - Polymorphic form of sepiapterin (2021-09-28),

10. 11072614 - Polymorphs of sepiapterin and salts thereof (2021-07-27),

11. 10975111 - Cardiopathy-reducing phosphodiester lipids (2021-04-13),

12. 10759792 - CaMKII inhibitors and uses thereof (2020-09-01),

13. 10081633 - Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof (2018-09-25),

14. 9951061 - CaMKII inhibitors and uses thereof (2018-04-24),

Title: The Innovations of Daniel Emil Levy

Introduction

Daniel Emil Levy is a prominent inventor based in San Mateo, California. He holds a total of 14 patents, showcasing his significant contributions to the field of pharmaceuticals. His work primarily focuses on the development of innovative treatments for diseases associated with low intracellular BH4 levels.

Latest Patents

Among his latest patents is the "Polymorphic form of sepiapterin." This patent discloses a crystalline form of sepiapterin, along with a method for preparing this crystalline form. It also includes pharmaceutical compositions containing the crystalline form and a method for treating patients with diseases linked to low intracellular BH4 levels. Another notable patent is "Polymorphs of sepiapterin and salts thereof." This patent details various crystalline forms of sepiapterin free base and their pharmaceutical applications. Sepiapterin is particularly useful in treating conditions such as phenylketonuria.

Career Highlights

Daniel has worked with several notable companies, including PTC Therapeutics, Inc. and Signpath Pharma, Inc. His experience in these organizations has allowed him to advance his research and development efforts in the pharmaceutical industry.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues such as James D. McChesney and Annie Bouchard. These partnerships have contributed to the success of his innovative projects.

Conclusion

Daniel Emil Levy's work in the field of pharmaceuticals has led to significant advancements in treatments for various diseases. His patents reflect his dedication to improving patient care through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.